Ozempic/Wegovy Tracker App

Important disclaimer: Semaglutide doses above 2.4mg weekly are not FDA-approved and are only available through compounding pharmacies under physician supervision. Limited clinical safety and efficacy data exists. The information below is for educational purposes only.

Some compounding pharmacies offer semaglutide at doses of 3mg or 4mg weekly, prescribed by physicians for patients who have plateaued at 2.4mg and have not achieved weight loss targets. The scientific rationale comes from preclinical dose-response data and observations from retatrutide trials — the highest-dose arm of retatrutide (12mg) showed dramatically superior results to lower doses, suggesting a clear dose-response curve for GLP-1R agonism exists beyond approved semaglutide doses.

Some physicians also experiment with split dosing — dividing the weekly 2.4mg dose into two 1.2mg twice-weekly injections. The rationale is to reduce peak plasma concentrations that drive GI side effects, while maintaining steady-state receptor activation. Some patients on twice-weekly 1.2mg report significantly better GI tolerability than weekly 2.4mg, making higher effective doses sustainable.

At higher doses, the side effect profile — particularly nausea, vomiting, and early satiety — scales predictably. Patients considering off-label higher doses should understand this tradeoff and work closely with a physician experienced in metabolic medicine or obesity medicine.